PHARMA INTELLIGENCE U.K. LIMITED

Active London
381 employees website.com
Life sciences and medical technology
P

PHARMA INTELLIGENCE U.K. LIMITED

Founded 7 Dec 2021 Active London, England 381 employees website.com
Life sciences and medical technology
Accounts Submitted 6 Jan 2026 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 17 Dec 2025 Next due 18 Dec 2026 7 months remaining
Net assets £-13M £2M 2024 year on year
Total assets £55M £34M 2024 year on year
Total Liabilities £68M £36M 2024 year on year
Charges 1
1 outstanding

Contact & Details

Contact

Registered Address

3 More London Riverside London SE1 2AQ England

Telephone

0800 000 0000

Website

www.example.com

Full company profile for PHARMA INTELLIGENCE U.K. LIMITED (13787459), an active life sciences and medical technology company based in London, England. Incorporated 7 Dec 2021. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2022–2024)

Cash in Bank

£11.00k

Decreased by £680.00k (-98%)

Net Assets

-£12.98M

Increased by £2.02M (+13%)

Total Liabilities

£68.32M

Decreased by £35.67M (-34%)

Turnover

£66.13M

Increased by £24.52M (+59%)

Employees

381

Increased by 137 (+56%)

Debt Ratio

123%

Increased by 6 (+5%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 1Feb 2022Acquisition
Investor 2Feb 2022Acquisition

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 3 Shares £19.22m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
30 Oct 20241$6.41m$6.41m
30 Oct 20241$6.41m$6.41m
30 Oct 20241$6.41m$6.41m

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (2)

Caerus Uk 1 Limited
100.0%
50,000,002
Caerus Uk 1 Limited
0.0%
301

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Caerus Uk 1 Limited

United Kingdom

Active
Notified 1 Jun 2022
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Informa Uk Limited

Ceased 1 Jun 2022

Ceased

Group Structure

Group Structure

CAERUS UK 1 LIMITED united kingdom
PHARMA INTELLIGENCE U.K. LIMITED Current Company
J&D CONSULTING LTD united kingdom

Charges

Charges

1 outstanding

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
11 Mar 2026OfficersTermination of Jay Nadler as director on 2026-03-11
11 Mar 2026OfficersAppointment of Mr Michael Douglas Gallup as director on 2026-03-11
9 Jan 2026ResolutionResolutions
6 Jan 2026AccountsAnnual accounts made up to 2024-12-31
2 Jan 2026InsolvencySolvency Statement dated 02/01/26
11 Mar 2026 Officers

Termination of Jay Nadler as director on 2026-03-11

11 Mar 2026 Officers

Appointment of Mr Michael Douglas Gallup as director on 2026-03-11

9 Jan 2026 Resolution

Resolutions

6 Jan 2026 Accounts

Annual accounts made up to 2024-12-31

2 Jan 2026 Insolvency

Solvency Statement dated 02/01/26

Recent Activity

Latest Activity

Termination of Jay Nadler as director on 2026-03-11

1 months ago on 11 Mar 2026

Appointment of Mr Michael Douglas Gallup as director on 2026-03-11

1 months ago on 11 Mar 2026

Resolutions

3 months ago on 9 Jan 2026

Annual accounts made up to 2024-12-31

3 months ago on 6 Jan 2026

Solvency Statement dated 02/01/26

3 months ago on 2 Jan 2026